Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1991 1
1994 3
1995 4
1997 2
1998 2
2000 3
2001 2
2002 2
2003 2
2004 1
2005 1
2007 2
2008 1
2009 4
2010 2
2011 7
2012 5
2013 5
2014 6
2015 5
2016 7
2017 6
2018 4
2019 2
2020 5
2021 4
2022 3
2023 2
2024 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

84 results

Results by year

Filters applied: . Clear all
Page 1
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, Ciruelos E, Schneeweiss A, Loi S, Monturus E, Clark E, Knott A, Restuccia E, Benyunes MC, Cortés J; CLEOPATRA study group. Swain SM, et al. Lancet Oncol. 2020 Apr;21(4):519-530. doi: 10.1016/S1470-2045(19)30863-0. Epub 2020 Mar 12. Lancet Oncol. 2020. PMID: 32171426 Clinical Trial.
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortés J; CLEOPATRA Study Group. Swain SM, et al. N Engl J Med. 2015 Feb 19;372(8):724-34. doi: 10.1056/NEJMoa1413513. N Engl J Med. 2015. PMID: 25693012 Free PMC article. Clinical Trial.
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM; CLEOPATRA Study Group. Baselga J, et al. N Engl J Med. 2012 Jan 12;366(2):109-19. doi: 10.1056/NEJMoa1113216. Epub 2011 Dec 7. N Engl J Med. 2012. PMID: 22149875 Free PMC article. Clinical Trial.
Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS).
Yamamoto Y, Iwata H, Taira N, Masuda N, Takahashi M, Yoshinami T, Ueno T, Toyama T, Yamanaka T, Takano T, Kashiwaba M, Tsugawa K, Hasegawa Y, Tamura K, Tada H, Hara F, Fujisawa T, Niikura N, Saji S, Morita S, Toi M, Ohno S. Yamamoto Y, et al. Among authors: kashiwaba m. Cancer Sci. 2022 Sep;113(9):3169-3179. doi: 10.1111/cas.15474. Epub 2022 Jul 23. Cancer Sci. 2022. PMID: 35754298 Free PMC article. Clinical Trial.
Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients.
Sawaki M, Taira N, Uemura Y, Saito T, Baba S, Kobayashi K, Kawashima H, Tsuneizumi M, Sagawa N, Bando H, Takahashi M, Yamaguchi M, Takashima T, Nakayama T, Kashiwaba M, Mizuno T, Yamamoto Y, Iwata H, Kawahara T, Ohashi Y, Mukai H; RESPECT study group. Sawaki M, et al. Among authors: kashiwaba m. J Clin Oncol. 2020 Nov 10;38(32):3743-3752. doi: 10.1200/JCO.20.00184. Epub 2020 Sep 16. J Clin Oncol. 2020. PMID: 32936713 Clinical Trial.
Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial.
Saji S, Taira N, Kitada M, Takano T, Takada M, Ohtake T, Toyama T, Kikawa Y, Hasegawa Y, Fujisawa T, Kashiwaba M, Ishida T, Nakamura R, Yamamoto Y, Toh U, Iwata H, Masuda N, Morita S, Ohno S, Toi M. Saji S, et al. Among authors: kashiwaba m. Lancet Oncol. 2022 May;23(5):636-649. doi: 10.1016/S1470-2045(22)00196-6. Epub 2022 Apr 8. Lancet Oncol. 2022. PMID: 35405087 Clinical Trial.
Cytological features of lymphoepithelioma-like carcinoma of the breast.
Sato A, Kawasaki T, Abo-Yashima A, Yoshida T, Kobayashi S, Kashiwaba M, Sugai T, Ichihara S. Sato A, et al. Among authors: kashiwaba m. Cytopathology. 2017 Apr;28(2):169-172. doi: 10.1111/cyt.12363. Epub 2016 Jul 31. Cytopathology. 2017. PMID: 27478161 No abstract available.
Long-term prognostic value of the GenesWell BCT score in Asian women with hormone receptor-positive/HER2-negative early breast cancer.
Fujiki Y, Kashiwaba M, Sato M, Kawano J, Teraoka M, Kanemitsu S, Rai Y, Taira T, Sagara Y, Ohi Y, Jo U, Lee YW, Lee SB, Gong G, Shin YK, Kwon MJ, Sagara Y. Fujiki Y, et al. Among authors: kashiwaba m. Breast Cancer. 2024 Jan;31(1):31-41. doi: 10.1007/s12282-023-01509-7. Epub 2023 Oct 9. Breast Cancer. 2024. PMID: 37812303 Free PMC article.
Laparoscopy-assisted appendectomy through an umbilical port in children.
Fukuzawa T, Mizuno M, Nakajima J, Nishizuka S, Kimura Y, Otsuka K, Nitta H, Kashiwaba M, Koeda K, Sasaki A, Wakabayashi G. Fukuzawa T, et al. Among authors: kashiwaba m. Asian J Endosc Surg. 2011 Feb;4(1):11-5. doi: 10.1111/j.1758-5910.2010.00069.x. Asian J Endosc Surg. 2011. PMID: 22776168
Eribulin versus S-1 as first or second-line chemotherapy to assess health-related quality of life and overall survival in HER2-negative metastatic breast cancer (RESQ study): a non-inferiority, randomised, controlled, open-label, phase 3 trial.
Takahashi M, Kikawa Y, Kashiwabara K, Taira N, Iwatani T, Shimozuma K, Ohtani S, Yoshinami T, Watanabe J, Kashiwaba M, Watanabe KI, Kitada M, Sakaguchi K, Tanabe Y, Aihara T, Mukai H. Takahashi M, et al. Among authors: kashiwaba m. EClinicalMedicine. 2024 Jul 16;74:102715. doi: 10.1016/j.eclinm.2024.102715. eCollection 2024 Aug. EClinicalMedicine. 2024. PMID: 39109189 Free PMC article.
84 results